✦ LIBER ✦

Issues in the development of practice guidelines for inflammatory bowel disease

✍ Scribed by Dr. William J. Tremaine

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 331 KB
Volume: 3
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.3780030407

No coin nor oath required. For personal study only.

✦ Synopsis

A

Practice guidelines for inflammatory bowel disease (IBD) should address the unique needs and challenges of the patients, to improve not only the quality of medical care but also the quality of life.

📜 SIMILAR VOLUMES

Guidelines for the management of growth

Guidelines for the management of growth failure in childhood inflammatory bowel disease

✍ Robert Heuschkel; Camilla Salvestrini; R. Mark Beattie; Hans Hildebrand; Thomas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

Around 1 in 4 patients with inflammatory bowel disease (IBD) present in childhood, the majority around the time of their pubertal growth spurt. This presents challenges over and above those of managing IBD in adults as this period is a time of dramatic psychological and physical transition for a chi

Role of diet in the development of infla

Role of diet in the development of inflammatory bowel disease

✍ Christine A. Chapman-Kiddell; Peter S.W. Davies; Lynda Gillen; Graham L. Radford 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

The inflammatory bowel diseases (IBDs) are a group of heterogeneous disorders characterized by acute and chronic inflammatory changes in the small or large bowel, or in both. Increasing incidence and prevalence figures for IBD both in the developed and developing world indicate that environmental fa

Drug development in inflammatory bowel d

Drug development in inflammatory bowel disease: The role of the FDA

✍ Conor Lahiff; Sunanda Kane; Alan C. Moss 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 1 views

All medicinal compounds sold in the United States for inflammatory bowel disease (IBD) are regulated by the Food and Drug Administration (FDA) via a number of regulations dating back to 1906. The primary contemporary role of the FDA is in the assessment of safety and efficacy, and subsequent marketi

Transitioning the adolescent inflammator

Transitioning the adolescent inflammatory bowel disease patient: Guidelines for the adult and pediatric gastroenterologist

✍ Yvette Leung; Melvin B. Heyman; Uma Mahadevan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Twenty percent of inflammatory bowel disease (IBD) patients present in the pediatric years, with recent reports suggesting a rising incidence in the pediatric age group. This highlights the need for both pediatric and adult gastroenterologists to better understand issues related to the process of tr

Development of extraintestinal manifesta

Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease

✍ Folashade Adebisi Jose; Elizabeth A. Garnett; Eric Vittinghoff; George D. Ferry; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

Background: Extraintestinal manifestations (EIMs) in pediatric patients with inflammatory bowel disease (IBD) are poorly characterized. We examined the prevalence of EIMs at diagnosis, subsequent incidence, and risk factors for EIMs. ## Methods: Data for 1649 patients from the PediIBD Consortium

Granulocyte-monocyte adsorptive apheresi

Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: Results, practical issues, safety, and future perspectives

✍ T. Ruuska; V. Wewer; F. Lindgren; P. Malmborg; M. Lindquist; L. Marthinsen; L. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

## Background: The purpose of the study was to collect data on granulocyte-monocyte adsorptive apheresis (gma) for the treatment of corticosteroid-dependent (sd) or corticosteroid-resistant (sr) inflammatory bowel disease (ibd) in children from 3 nordic countries to evaluate its efficacy and safety